MT 3724

Drug Profile

MT 3724

Alternative Names: MT3724

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Molecular Templates
  • Developer Banner MD Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Molecular Templates; University of Arizona; University of Texas M. D. Anderson Cancer Center
  • Class Antibodies; Antineoplastics; Bacterial toxins; Immunoconjugates
  • Mechanism of Action CD20 antigen inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diffuse large B cell lymphoma
  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 28 Mar 2018 Efficacy and adverse events data from a phase I trial in Diffuse large B-cell lymphoma released by Molecular Templates
  • 28 Mar 2018 Efficacy data from a phase I combined trial (phase I dose-finding and phase Ib expansion trial) in Diffuse large B-cell lymphoma released by Molecular Templates
  • 28 Mar 2018 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Second-line therapy or greater) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top